Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 767

Sort by

Sort Order Select

Journal Articles

Discovery and characterization of targetable NTRK point mutations in hematologic neoplasms

Sunil K. Joshi, Kristin Qian, William H. Bisson, Kevin Watanabe-Smith, Ariane Huang, Daniel Bottomly, Elie Traer, Jeffrey W. Tyner, Shannon K. McWeeney, Monika A. Davare, Brian J. Druker, Cristina E. Tognon

Blood (2020) 135 (24): 2159–2170.

https://doi.org/10.1182/blood.2019003691

Published: 2020

Includes: Supplemental data

Journal Articles

ROR1 Targeted Immunoliposomal Delivery of OSU-2S Show Selective Cytotoxicity in t(1;19) Translocated B-ALL

Swagata Goswami, MSc, Chi-Ling Chiang, PhD, Kevan Zapolnik, BS, Zhiliang Xie, James L. Lee, PhD, Sivasubramanian Baskar, Christoph Rader, PhD, John C. Byrd, MD, Mitch A. Phelps, PhD, Bhavana Bhatnagar, DO, Natarajan Muthusamy, DVM,PhD

Blood (2019) 134 (Supplement_1): 3798.

https://doi.org/10.1182/blood-2019-128828

Published: 2019

Journal Articles

Safety and Efficacy of Midostaurin in Combination with High-Dose Daunorubicin in 7+3 Induction for Acute Myeloid Leukemia with FLT3 Mutation

Yehuda E. Deutsch, MD, Robert Wilkinson, PharmD, Amanda Brahim, PharmD, Stephanie Boisclair, MD, Jose Sandoval-Sus, MD, Annie Kuehnel, APRN, Terrence J Bradley, MD, Chetasi Talati, MD, Ellen Madarang, PharmD, Jillian Lykon, PharmD, Justin M. Watts, MD, David A Sallman, MD, Kendra L. Sweet, MD, Jeffrey E. Lancet, MD, Hugo F. Fernandez, MD

Blood (2019) 134 (Supplement_1): 3896.

https://doi.org/10.1182/blood-2019-129331

Published: 2019

Journal Articles

Overcoming Adaptive Therapy Resistance in AML By Targeting Immune Response Pathways

Blood (2019) 134 (Supplement_1): 3934.

https://doi.org/10.1182/blood-2019-124178

Published: 2019

Journal Articles

A Phase I/II Study of NMS-03592088, a FLT3, KIT and CSF1R Inhibitor, in Patients with Relapsed or Refractory AML or CMML

Blood (2019) 134 (Supplement_1): 3855.

https://doi.org/10.1182/blood-2019-121954

Published: 2019

Journal Articles

Targeting Activated Signaling Pathways for the Treatment of IKZF1 -Deleted B Lymphoblastic Leukemia

Rohit Gupta, BA, Jason H. Rogers, MS, Xin Long, PhD, Geraldo Medrano, BS, Jaime M. Reyes, BS, Michele Redell, MD PhD, Zachary T Ball, PhD, Margaret Goodell, PhD, Rachel E. Rau, MD

Blood (2019) 134 (Supplement_1): 3789.

https://doi.org/10.1182/blood-2019-127209

Published: 2019

Journal Articles

Durable Responses Observed in Elderly AML Patients Unfit for Intensive Chemotherapy with First-in Class Selective AXL Inhibitor Bemcentinib (BGB324) in Combination with LDAC: Phase II Open-Label Study

Blood (2019) 134 (Supplement_1): 3943.

https://doi.org/10.1182/blood-2019-128683

Published: 2019

Journal Articles

Targeting Neurotrophic Receptor Tyrosine Kinase (NTRK) Fusion Structural Homologs in Refractory Pediatric Acute Lymphoblastic Leukemia (ALL)

Son Tran, Mehul Gupta, Sunand Kannappan, Chunfen Zhang, MD, Aru Narendran, MD PhD

Blood (2019) 134 (Supplement_1): 3882.

https://doi.org/10.1182/blood-2019-132223

Published: 2019

Journal Articles

Receptor Tyrosine Kinase AXL: A Potential Strategy to Counter Immune Suppression and Dormancy in Multiple Myeloma

Kim De Veirman, Siyang Yan, Ken Maes, Nathan De Beule, MD, Sylvia Faict, MSc, Elke De Bruyne, PhD, Eline Menu, PhD, Karin Vanderkerken, PhD

Blood (2019) 134 (Supplement_1): 4335.

https://doi.org/10.1182/blood-2019-126834

Published: 2019

Journal Articles

Impact and Outcomes of RAS gene Mutations in Core Binding Factor Acute Myeloid Leukemia

Hassan Awada, Ashwin Kishtagari, MBBS, Teodora Kuzmanovic, Jibran Durrani, Cassandra M Kerr, MS, Manja Meggendorfer, PhD, Anjali S. Advani, MD, Aziz Nazha, MD, Hetty E. Carraway, MD MBA, Torsten Haferlach, MD, Mikkael A. Sekeres, MD MS, Valeria Visconte, PhD, Jaroslaw P. Maciejewski, MD PhD

Blood (2019) 134 (Supplement_1): 2720.

https://doi.org/10.1182/blood-2019-131301

Published: 2019

Journal Articles

Combination of the MEK Inhibitor Trametinib and Pyrvinium Pamoate Efficiently Targets RAS Pathway-Mutated Acute Myeloid Leukemia in Preclinical Models

Blood (2019) 134 (Supplement_1): 2671.

https://doi.org/10.1182/blood-2019-123418

Published: 2019

Journal Articles

Evaluating ROR1 As a Target in Childhood Leukemia

Paraskevi Diamanti, PhD, Bethan Kathleen Bailey, BSc, Obinna Ebere Iheanacho, MD, Amit C. Nathwani, MD PhD, Allison Blair, PhD

Blood (2019) 134 (Supplement_1): 2635.

https://doi.org/10.1182/blood-2019-126734

Published: 2019

Journal Articles

CD117 Expression Is Associated with Cytogenetic and Molecular Profiles and Outcome in Pediatric Acute Myeloid Leukemia

Katherine Tarlock, MD, Lisa Eidenschink Brodersen, PhD, Todd A. Alonzo, PhD, Yi-Cheng Wang, Robert B. Gerbing, Laura Pardo, Fangyan Dai, Alan S Gamis, MD MPH, Richard Aplenc, MD PhD, Jessica A. Pollard, MD, Michael R. Loken, PhD, Soheil Meshinchi, MD PhD

Blood (2019) 134 (Supplement_1): 2699.

https://doi.org/10.1182/blood-2019-127100

Published: 2019

Journal Articles

FLT3 Is Sumoylated and Localizes to the Nucleus in Acute Myeloid Leukemia

Marisse Asong, MD MSc, Julhash Uddin Kazi, PhD, Lars Ronnstrand, PhD

Blood (2019) 134 (Supplement_1): 2733.

https://doi.org/10.1182/blood-2019-127914

Published: 2019

Journal Articles

Diffuse Large B Cell Lymphoma (DLBCL) Expresses ROR1 and a ROR1 Small Molecule Inhibitor (KAN0441571C) Induced Significant Apoptosis of Tumor Cells

Mohammad Hojjat-Farsangi, MSc,PhD, Amineh Ghaderi, MSc, AmirHossein Daneshmanesh, MD PhD, Jemina Lehto, MSc, Ali Moshfegh, MSc,PhD, Parviz Kokhaei, MSc,PhD, Jan Vågberg, MSc,PhD, Elisabeth Olsson, MSc,PhD, Charlotta Löfberg, MSc,PhD, Charlotta Carina Norström, MSc,PhD, Johan Schultz, MSc,PhD, Martin Norin, MSc,PhD, Thomas Olin, MSc,PhD, Elias Drakos, MD PhD Prof., George Z. Rassidakis, MD PhD Prof., Anders Österborg, MD PhD, Håkan Mellstedt, MD PhD Prof.

Blood (2019) 134 (Supplement_1): 2565.

https://doi.org/10.1182/blood-2019-126801

Published: 2019

Journal Articles

Vls-101 Is a Novel Therapeutic Antibody-Drug Conjugate (ADC) Targeting Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1) in Richter's Syndrome (RS)

Tiziana Vaisitti, PhD, Katti Jessen, PhD, Thanh-Trang Vo, PhD, Mira Ko, Francesca Arruga, PhD, Nicoletta Vitale, PhD, Esteban Braggio, PhD, Arianna Di Napoli, Amy Chadburn, MD, John N. Allan, MD, Richard R. Furman, MD, Langdon L. Miller, Brian J Lanutti, PhD, Silvia Deaglio, MD PhD

Blood (2019) 134 (Supplement_1): 2856.

https://doi.org/10.1182/blood-2019-126827

Published: 2019

Journal Articles

ETH-155008, a Novel Selective Dual Inhibitor of FLT3 and CDK4/6 in Preclinical Treatment of Acute Myeloid Leukemia

Changnian Liu, PhD MD, Bin Liu, MSc, Chunping Xu, PhD, Pan Zhang, Bin Li, Bin Ji, Bin Zhang, Qingjun Liu, PhD, James Zhang, MSc, Chengzhi Yu, PhD

Blood (2019) 134 (Supplement_1): 5141.

https://doi.org/10.1182/blood-2019-123589

Published: 2019

Journal Articles

Transmembrane Receptors, Cytoskeleton and Cell Cycle Genes Were Progressively Deregulated in the Bone Marrow CD19+ and CD138+ Cells of Patientswwith Waldenstrom's Macroglolubinemia (WM) Vs. Subjects with IgM Monoclonal Gammopathy of Undetermined Significance Igmmgus Vs. Healthy Subjects

Alessandra Trojani, Alessandra Tedeschi, MD, Annamaria Maria Frustaci, Marina Deodato, Luca Emanuele Bossi, Barbara Di Camillo, Marco Montillo, MD, Enrica Morra, Roberto Cairoli, MD

Blood (2019) 134 (Supplement_1): 5036.

https://doi.org/10.1182/blood-2019-125577

Published: 2019

Journal Articles

Apatinib Exhibits Cytotoxicity to Acute Myeloid Leukemia Cell Via Targeting VEGFR2-Mediated Pro-Survival Signaling and Angiogenesis

Lian Yu, Manman Deng, Zhifeng Li, Zhihong Fang, Yun Dai, MD, Bing Xu

Blood (2019) 134 (Supplement_1): 5158.

https://doi.org/10.1182/blood-2019-123472

Published: 2019

Journal Articles

Investigation of New Therapeutic Compounds for Juvenile Myelomonocytic Leukemia Using Induced Pluripotent Stem Cells with Stably Activated Ras Pathway

Lisa Maria Kuhn, Cyrill Schipp, PhD, Daniel Hein, PhD, Bianca Killing, Nan Qin, PhD, Vera H Jepsen, M.Sc., Heinz Ahlert, MSc, BSc, Jasmin Bartl, PhD, Viktoria Marquardt, M.Sc., David Pauck, Kai Völtzke, M.Sc., Jonathan Lim, PhD, Gabriel Leprivier, PhD, Marc Remke, MD, Sanil Bhatia, PhD, Thorsten Rosenbaum, MD, Arndt Borkhardt, MD, Ute Fischer, PhD

Blood (2019) 134 (Supplement_1): 4651.

https://doi.org/10.1182/blood-2019-131406

Published: 2019

NARROW

Discovery and characterization of targetable NTRK point mutations in hematologic neoplasms

ROR1 Targeted Immunoliposomal Delivery of OSU-2S Show Selective Cytotoxicity in t(1;19) Translocated B-ALL

Safety and Efficacy of Midostaurin in Combination with High-Dose Daunorubicin in 7+3 Induction for Acute Myeloid Leukemia with FLT3 Mutation

Overcoming Adaptive Therapy Resistance in AML By Targeting Immune Response Pathways

A Phase I/II Study of NMS-03592088, a FLT3, KIT and CSF1R Inhibitor, in Patients with Relapsed or Refractory AML or CMML

Targeting Activated Signaling Pathways for the Treatment of IKZF1 -Deleted B Lymphoblastic Leukemia

Durable Responses Observed in Elderly AML Patients Unfit for Intensive Chemotherapy with First-in Class Selective AXL Inhibitor Bemcentinib (BGB324) in Combination with LDAC: Phase II Open-Label Study

Targeting Neurotrophic Receptor Tyrosine Kinase (NTRK) Fusion Structural Homologs in Refractory Pediatric Acute Lymphoblastic Leukemia (ALL)

Receptor Tyrosine Kinase AXL: A Potential Strategy to Counter Immune Suppression and Dormancy in Multiple Myeloma

Impact and Outcomes of RAS gene Mutations in Core Binding Factor Acute Myeloid Leukemia

Combination of the MEK Inhibitor Trametinib and Pyrvinium Pamoate Efficiently Targets RAS Pathway-Mutated Acute Myeloid Leukemia in Preclinical Models

Evaluating ROR1 As a Target in Childhood Leukemia

CD117 Expression Is Associated with Cytogenetic and Molecular Profiles and Outcome in Pediatric Acute Myeloid Leukemia

FLT3 Is Sumoylated and Localizes to the Nucleus in Acute Myeloid Leukemia

Diffuse Large B Cell Lymphoma (DLBCL) Expresses ROR1 and a ROR1 Small Molecule Inhibitor (KAN0441571C) Induced Significant Apoptosis of Tumor Cells

Vls-101 Is a Novel Therapeutic Antibody-Drug Conjugate (ADC) Targeting Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1) in Richter's Syndrome (RS)

ETH-155008, a Novel Selective Dual Inhibitor of FLT3 and CDK4/6 in Preclinical Treatment of Acute Myeloid Leukemia

Transmembrane Receptors, Cytoskeleton and Cell Cycle Genes Were Progressively Deregulated in the Bone Marrow CD19+ and CD138+ Cells of Patientswwith Waldenstrom's Macroglolubinemia (WM) Vs. Subjects with IgM Monoclonal Gammopathy of Undetermined Significance Igmmgus Vs. Healthy Subjects

Apatinib Exhibits Cytotoxicity to Acute Myeloid Leukemia Cell Via Targeting VEGFR2-Mediated Pro-Survival Signaling and Angiogenesis

Investigation of New Therapeutic Compounds for Juvenile Myelomonocytic Leukemia Using Induced Pluripotent Stem Cells with Stably Activated Ras Pathway

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only